App-Quantinova.ai

Can lay health workers achieve the triple aim? Results from the Engagement of Patients with Advanced Cancer (EPAC) trial.

Manali I. Patel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

12 month survival for oncology patients with versus without patient navigation.

Marc Kowalkowski - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Exploration of the ASCO and ESMO value frameworks for cancer drugs.

Daniel Lin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Financial ties to industry among national comprehensive cancer network guideline authors.

Aaron Philip Mitchell - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The economic impact of the transition from branded to generic oncology drugs.

Winson Y. Cheung - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Food and Drug Administration analysis of 1332 single patient and emergency use expanded access (compassionate use) requests for patients with cancer over a duration of three years (2012-2014).

Steven J. Lemery - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

End of life services for cancer patients: A population-based evaluation.

Scott David Ramsey - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Accuracy of a model to predict cancer trial accrual compared to prediction accuracy by investigators at sixteen cancer centers.

Wendy R. Tate - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of pre-diagnosis major depressive disorder and health-related quality of life on treatment choice for ductal carcinoma in situ in older women.

Daniela Lemos Buscariollo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

An unexplored intersection of patient care: Analyses of cancer related emergency department utilization.

Donna Rivera - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Financial burden in adult cancer survivors: Care affordability and accessibility.

Ryan David Nipp - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

State mandated insurance benefits and off-label use of cancer drugs.

Fabrice Smieliauskas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Will a national communication campaign to increase awareness of clinical trials work?

Holly A. Massett - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Outcomes in metastatic cancer patients who develop spinal cord compression.

Achuta Kumar Guddati - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The messenger matters: Relative influence of oncologists versus other care team members on advanced cancer patients illness understanding.

Simon Mentis Cohen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Association of minority-serving hospitals with lower resources for cancer care.

Kim Felder Rhoads - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Ethnic/racial and socioeconomic disparities as predictors of behavioral risk factors among 7559 cancer survivors.

Matthew Asare - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of marital status on the survival of patients with hematologic malignancies reported to the California Cancer Registry.

Matthew Joseph Wieduwilt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A population-based study of racial/ethnic disparities in cancer survival among adolescents and young adults.

Meryl Colton - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Differences in the molecular landscape of cancer between African American (AA) and Caucasian (CC) cancer patients.

Elisabeth I. Heath - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts